In response to: Benefit of neoral C2 monitoring in de novo cardiac transplant recipients receiving basiliximab induction

Transplantation. 2008 Sep 27;86(6):885; author reply 886. doi: 10.1097/TP.0b013e3181861f77.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / therapeutic use*
  • Basiliximab
  • Drug Administration Schedule
  • Female
  • Heart Transplantation / immunology*
  • Heart Transplantation / mortality
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / therapeutic use*
  • Male
  • Monitoring, Physiologic
  • Recombinant Fusion Proteins / administration & dosage
  • Recombinant Fusion Proteins / therapeutic use*
  • Survival Analysis

Substances

  • Antibodies, Monoclonal
  • Immunosuppressive Agents
  • Recombinant Fusion Proteins
  • Basiliximab